<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.2.475">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">


<title>Type 2 diabetes in migrants: a register-based analysis - 1&nbsp; Introduction</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1.6em;
  vertical-align: middle;
}
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>


<script src="site_libs/quarto-nav/quarto-nav.js"></script>
<script src="site_libs/quarto-nav/headroom.min.js"></script>
<script src="site_libs/clipboard/clipboard.min.js"></script>
<script src="site_libs/quarto-search/autocomplete.umd.js"></script>
<script src="site_libs/quarto-search/fuse.min.js"></script>
<script src="site_libs/quarto-search/quarto-search.js"></script>
<meta name="quarto:offset" content="./">
<link href="./2-aims.html" rel="next">
<link href="./0-abbreviations.html" rel="prev">
<script src="site_libs/quarto-html/quarto.js"></script>
<script src="site_libs/quarto-html/popper.min.js"></script>
<script src="site_libs/quarto-html/tippy.umd.min.js"></script>
<script src="site_libs/quarto-html/anchor.min.js"></script>
<link href="site_libs/quarto-html/tippy.css" rel="stylesheet">
<link href="site_libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="site_libs/bootstrap/bootstrap.min.js"></script>
<link href="site_libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="site_libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">
<script id="quarto-search-options" type="application/json">{
  "location": "sidebar",
  "copy-button": false,
  "collapse-after": 3,
  "panel-placement": "start",
  "type": "textbox",
  "limit": 20,
  "language": {
    "search-no-results-text": "No results",
    "search-matching-documents-text": "matching documents",
    "search-copy-link-title": "Copy link to search",
    "search-hide-matches-text": "Hide additional matches",
    "search-more-match-text": "more match in this document",
    "search-more-matches-text": "more matches in this document",
    "search-clear-button-title": "Clear",
    "search-detached-cancel-button-title": "Cancel",
    "search-submit-button-title": "Submit"
  }
}</script>

  <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml-full.js" type="text/javascript"></script>

</head>

<body class="nav-sidebar floating">

<div id="quarto-search-results"></div>
  <header id="quarto-header" class="headroom fixed-top">
  <nav class="quarto-secondary-nav" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar" aria-controls="quarto-sidebar" aria-expanded="false" aria-label="Toggle sidebar navigation" onclick="if (window.quartoToggleHeadroom) { window.quartoToggleHeadroom(); }">
    <div class="container-fluid d-flex justify-content-between">
      <h1 class="quarto-secondary-nav-title"><span class="chapter-number">1</span>&nbsp; <span class="chapter-title">Introduction</span></h1>
      <button type="button" class="quarto-btn-toggle btn" aria-label="Show secondary navigation">
        <i class="bi bi-chevron-right"></i>
      </button>
    </div>
  </nav>
</header>
<!-- content -->
<div id="quarto-content" class="quarto-container page-columns page-rows-contents page-layout-article">
<!-- sidebar -->
  <nav id="quarto-sidebar" class="sidebar collapse sidebar-navigation floating overflow-auto">
    <div class="pt-lg-2 mt-2 text-left sidebar-header">
    <div class="sidebar-title mb-0 py-0">
      <a href="./">Type 2 diabetes in migrants: a register-based analysis</a> 
    </div>
      </div>
      <div class="mt-2 flex-shrink-0 align-items-center">
        <div class="sidebar-search">
        <div id="quarto-search" class="" title="Search"></div>
        </div>
      </div>
    <div class="sidebar-menu-container"> 
    <ul class="list-unstyled mt-1">
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./index.html" class="sidebar-item-text sidebar-link">Cover Page</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./0-disclosure.html" class="sidebar-item-text sidebar-link">Notes and disclosures</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./0-preface.html" class="sidebar-item-text sidebar-link">Preface</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./0-abbreviations.html" class="sidebar-item-text sidebar-link">Abbreviations</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./1-introduction.html" class="sidebar-item-text sidebar-link active"><span class="chapter-number">1</span>&nbsp; <span class="chapter-title">Introduction</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./2-aims.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">2</span>&nbsp; <span class="chapter-title">Aims</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./3-methods.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">3</span>&nbsp; <span class="chapter-title">Material and methods</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./4-results.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">4</span>&nbsp; <span class="chapter-title">Results in summary</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./5-discussion-methods.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">5</span>&nbsp; <span class="chapter-title">Discussion of methods</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./6-discussion-results.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">6</span>&nbsp; <span class="chapter-title">Discussion of results</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./7-conclusions.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">7</span>&nbsp; <span class="chapter-title">Conclusions</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./8-perspectives.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">8</span>&nbsp; <span class="chapter-title">Perspectives and future research</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./references.html" class="sidebar-item-text sidebar-link">References</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./summary-english.html" class="sidebar-item-text sidebar-link">English summary</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./summary-danish.html" class="sidebar-item-text sidebar-link">Dansk resumé</a>
  </div>
</li>
        <li class="sidebar-item sidebar-item-section">
      <div class="sidebar-item-container"> 
            <a class="sidebar-item-text sidebar-link text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-1" aria-expanded="true">Appendices</a>
          <a class="sidebar-item-toggle text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-1" aria-expanded="true">
            <i class="bi bi-chevron-right ms-2"></i>
          </a> 
      </div>
      <ul id="quarto-sidebar-section-1" class="collapse list-unstyled sidebar-section depth1 show">  
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./app1-supplementary.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">A</span>&nbsp; <span class="chapter-title">Supplementary validation analyses</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./app2-papers.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">B</span>&nbsp; <span class="chapter-title">Full papers</span></a>
  </div>
</li>
      </ul>
  </li>
    </ul>
    </div>
</nav>
<!-- margin-sidebar -->
    <div id="quarto-margin-sidebar" class="sidebar margin-sidebar">
        <nav id="TOC" role="doc-toc" class="toc-active">
    <h2 id="toc-title">Table of contents</h2>
   
  <ul>
  <li><a href="#migrants-and-type-2-diabetes" id="toc-migrants-and-type-2-diabetes" class="nav-link active" data-scroll-target="#migrants-and-type-2-diabetes"><span class="toc-section-number">1.1</span>  Migrants and type 2 diabetes</a></li>
  <li><a href="#migrants-in-denmark" id="toc-migrants-in-denmark" class="nav-link" data-scroll-target="#migrants-in-denmark"><span class="toc-section-number">1.2</span>  Migrants in Denmark</a>
  <ul class="collapse">
  <li><a href="#migration" id="toc-migration" class="nav-link" data-scroll-target="#migration"><span class="toc-section-number">1.2.1</span>  Migration</a></li>
  <li><a href="#migrants-in-the-danish-data-infrastructure" id="toc-migrants-in-the-danish-data-infrastructure" class="nav-link" data-scroll-target="#migrants-in-the-danish-data-infrastructure"><span class="toc-section-number">1.2.2</span>  Migrants in the Danish data infrastructure</a></li>
  <li><a href="#migrant-groups-in-denmark" id="toc-migrant-groups-in-denmark" class="nav-link" data-scroll-target="#migrant-groups-in-denmark"><span class="toc-section-number">1.2.3</span>  Migrant groups in Denmark</a></li>
  <li><a href="#descendants" id="toc-descendants" class="nav-link" data-scroll-target="#descendants"><span class="toc-section-number">1.2.4</span>  Descendants</a></li>
  </ul></li>
  <li><a href="#type-2-diabetes-care" id="toc-type-2-diabetes-care" class="nav-link" data-scroll-target="#type-2-diabetes-care"><span class="toc-section-number">1.3</span>  Type 2 diabetes care</a>
  <ul class="collapse">
  <li><a href="#complications-and-risk-factors" id="toc-complications-and-risk-factors" class="nav-link" data-scroll-target="#complications-and-risk-factors"><span class="toc-section-number">1.3.1</span>  Complications and risk factors</a></li>
  <li><a href="#pharmacological-treatment" id="toc-pharmacological-treatment" class="nav-link" data-scroll-target="#pharmacological-treatment"><span class="toc-section-number">1.3.2</span>  Pharmacological treatment</a></li>
  <li><a href="#monitoring" id="toc-monitoring" class="nav-link" data-scroll-target="#monitoring"><span class="toc-section-number">1.3.3</span>  Monitoring</a></li>
  </ul></li>
  <li><a href="#clinical-guidelines-for-type-2-diabetes-care" id="toc-clinical-guidelines-for-type-2-diabetes-care" class="nav-link" data-scroll-target="#clinical-guidelines-for-type-2-diabetes-care"><span class="toc-section-number">1.4</span>  Clinical guidelines for type 2 diabetes care</a>
  <ul class="collapse">
  <li><a href="#context" id="toc-context" class="nav-link" data-scroll-target="#context"><span class="toc-section-number">1.4.1</span>  Context</a></li>
  <li><a href="#diagnosis" id="toc-diagnosis" class="nav-link" data-scroll-target="#diagnosis"><span class="toc-section-number">1.4.2</span>  Diagnosis</a></li>
  <li><a href="#monitoring-1" id="toc-monitoring-1" class="nav-link" data-scroll-target="#monitoring-1"><span class="toc-section-number">1.4.3</span>  Monitoring</a></li>
  <li><a href="#biomarker-levels" id="toc-biomarker-levels" class="nav-link" data-scroll-target="#biomarker-levels"><span class="toc-section-number">1.4.4</span>  Biomarker levels</a></li>
  <li><a href="#pharmacological-treatment-1" id="toc-pharmacological-treatment-1" class="nav-link" data-scroll-target="#pharmacological-treatment-1"><span class="toc-section-number">1.4.5</span>  Pharmacological treatment</a></li>
  </ul></li>
  <li><a href="#sec-id-t2d-registers" id="toc-sec-id-t2d-registers" class="nav-link" data-scroll-target="#sec-id-t2d-registers"><span class="toc-section-number">1.5</span>  Identification of type 2 diabetes cases in healthcare registers</a>
  <ul class="collapse">
  <li><a href="#danish-register-data-infrastructure" id="toc-danish-register-data-infrastructure" class="nav-link" data-scroll-target="#danish-register-data-infrastructure"><span class="toc-section-number">1.5.1</span>  Danish register data infrastructure</a></li>
  <li><a href="#benefits" id="toc-benefits" class="nav-link" data-scroll-target="#benefits"><span class="toc-section-number">1.5.2</span>  Benefits</a></li>
  <li><a href="#challenges" id="toc-challenges" class="nav-link" data-scroll-target="#challenges"><span class="toc-section-number">1.5.3</span>  Challenges</a></li>
  <li><a href="#sec-register-based-diabetes-classifiers" id="toc-sec-register-based-diabetes-classifiers" class="nav-link" data-scroll-target="#sec-register-based-diabetes-classifiers"><span class="toc-section-number">1.5.4</span>  Register-based diabetes classifiers</a></li>
  </ul></li>
  <li><a href="#introduction-at-a-glance" id="toc-introduction-at-a-glance" class="nav-link" data-scroll-target="#introduction-at-a-glance"><span class="toc-section-number">1.6</span>  Introduction at a glance</a></li>
  </ul>
</nav>
    </div>
<!-- main -->
<main class="content" id="quarto-document-content">

<header id="title-block-header" class="quarto-title-block default">
<div class="quarto-title">
<h1 class="title"><span id="sec-introduction" class="quarto-section-identifier d-none d-lg-block"><span class="chapter-number">1</span>&nbsp; <span class="chapter-title">Introduction</span></span></h1>
</div>



<div class="quarto-title-meta">

    
  
    
  </div>
  

</header>

<p>This chapter describes type 2 diabetes (T2D) and how migrants are at particular risk. It then outlines the context of migration and health care in Denmark and summarizes clinical guideline recommendations and how they relate to the needs of migrants with T2D. Finally, it introduces the reader to identification of diabetes patients in Danish healthcare registers as a means to providing knowledge on potential disparities in T2D care between migrants and native Danes.</p>
<section id="migrants-and-type-2-diabetes" class="level2" data-number="1.1">
<h2 data-number="1.1" class="anchored" data-anchor-id="migrants-and-type-2-diabetes"><span class="header-section-number">1.1</span> Migrants and type 2 diabetes</h2>
<p>T2D constitutes the vast majority of all diabetes cases, and disproportionally affects the socially deprived demographics in societies across the globe.<span class="citation" data-cites="socialdiabetes"><sup><a href="references.html#ref-socialdiabetes" role="doc-biblioref">1</a></sup></span> Today, the prevalence of type 2 diabetes (T2D) exceeds half a <em>billion</em> people globally and is on the rise due to several factors, including population ageing, urbanization, adoption of energy-dense diets, and sedentary lifestyles. These transitions are occurring at a rapid pace in developing countries, where they affect the largest number of people. Furthermore, many developing countries have populations with a genetic predisposition to developing T2D, which exacerbates the impact of these transitions.<span class="citation" data-cites="diabetesatlas"><sup><a href="references.html#ref-diabetesatlas" role="doc-biblioref">2</a></sup></span></p>
<p>After being granted residence permit in Denmark and other developed nations, migrants are often housed in densely-populated urban areas and are exposed to drastic lifestyle transitions. Migrants may also suffer from previous mental and physical trauma, which - in addition to cultural and language barriers - can limit their ability to gain higher-income employment and escape their disadvantageous socioeconomic position.<span class="citation" data-cites="eurostat_migrants"><sup><a href="references.html#ref-eurostat_migrants" role="doc-biblioref">3</a></sup></span> This leaves migrants particularly vulnerable to T2D, as they are positioned at the point of convergence of these exposures: genetic predisposition, rapid lifestyle transitions, and the disparate social impact of T2D.</p>
<p>In Denmark and many other developed nations, healthcare systems are facing a challenge to sustain the expected high quality of care in an ageing population with a growing burden of chronic diseases and comorbidities.<span class="citation" data-cites="eurostat_popstruct eurostat_ageing_europe"><sup><a href="references.html#ref-eurostat_popstruct" role="doc-biblioref">4</a>,<a href="references.html#ref-eurostat_ageing_europe" role="doc-biblioref">5</a></sup></span> Prioritisation of limited resources is crucial to ensure that those with the highest need for (and potential benefit from) healthcare receive adequate care. Migrant origin is a well-established risk factor of T2D, and migrants have a higher prevalence of T2D compared to native populations today, but the increased risk of developing T2D is partially mitigated by their younger age.<span class="citation" data-cites="meeks2016 andersen2016"><sup><a href="references.html#ref-meeks2016" role="doc-biblioref">6</a>,<a href="references.html#ref-andersen2016" role="doc-biblioref">7</a></sup></span> However, this only delays the impact of their increased T2D risk. As these migrant populations age in the coming years, they will make up a growing proportion of T2D patients in the country. In 2019, 9% of immigrants in Denmark were aged 66 years and above, a proportion projected to have doubled by 2039.<span class="citation" data-cites="befpyramide"><sup><a href="references.html#ref-befpyramide" role="doc-biblioref">8</a></sup></span> Therefore, understanding potential disparities in care and the specific healthcare needs of migrant populations with T2D can inform the prioritisation of healthcare resources, ultimately ensuring that all individuals with T2D can continue to receive appropriate care.</p>
<p>Currently, there is a lack of evidence on T2D care in migrants, and research in this area faces several challenges that may explain the scarcity of evidence. Not only are migrants a minority, which limits the size of potential study populations, they are often a hard-to-reach group in studies that require patient engagement for inclusion, which exacerbates sample size problems and can induce selection bias.<span class="citation" data-cites="nonresponse_migrants"><sup><a href="references.html#ref-nonresponse_migrants" role="doc-biblioref">9</a></sup></span> Furthermore, migrants have historically been defined by their racial appearance and ethnic minorities categorised accordingly, particularly in Europe and the United States. While these categories allow researchers to identify racial minorities, they obscure the role of migrants in the modern era, and provide only indirect evidence on migrant minority groups.<span class="citation" data-cites="erayil2021raceethnicity"><sup><a href="references.html#ref-erayil2021raceethnicity" role="doc-biblioref">10</a></sup></span></p>
</section>
<section id="migrants-in-denmark" class="level2" data-number="1.2">
<h2 data-number="1.2" class="anchored" data-anchor-id="migrants-in-denmark"><span class="header-section-number">1.2</span> Migrants in Denmark</h2>
<p>In 2019, Denmark had a population of approximately 5.8 million residents, of whom 600,000 (10%) were migrants and 1 million (18%) were aged 66 years and older. By 2039, the population is expected to have grown to 6.2 million, with a migrant population of 750,000 (12%) and 1.5 million individuals (23%) aged 66 years and older. <a href="#fig-demo-pyramids">Figure&nbsp;<span>1.1</span></a> shows the projected demographics of native Danes and migrants in 2039 (2019 demographics outlined in light green (adapted from Statistics Denmark).<span class="citation" data-cites="befpyramide"><sup><a href="references.html#ref-befpyramide" role="doc-biblioref">8</a></sup></span></p>
<div id="fig-demo-pyramids" class="quarto-layout-panel">
<figure class="figure">
<div class="quarto-layout-row quarto-layout-valign-top">
<div class="quarto-layout-cell quarto-layout-cell-subref" style="flex-basis: 50.0%;justify-content: center;">
<div id="fig-pyramid-native-danes" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<p><img src="figures/pyramid_native_danes.png" class="img-fluid figure-img" data-ref-parent="fig-demo-pyramids"></p>
<p></p><figcaption class="figure-caption">(a) Native Danes 2019-2039</figcaption><p></p>
</figure>
</div>
</div>
<div class="quarto-layout-cell quarto-layout-cell-subref" style="flex-basis: 50.0%;justify-content: center;">
<div id="fig-pyramid-migrants" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<p><img src="figures/pyramid_migrants.png" class="img-fluid figure-img" data-ref-parent="fig-demo-pyramids"></p>
<p></p><figcaption class="figure-caption">(b) Migrants 2019-2039</figcaption><p></p>
</figure>
</div>
</div>
</div>
<p></p><figcaption class="figure-caption">Figure&nbsp;1.1: <strong>Demographic projections of native Danes and migrants</strong></figcaption><p></p>
</figure>
</div>
<section id="migration" class="level3" data-number="1.2.1">
<h3 data-number="1.2.1" class="anchored" data-anchor-id="migration"><span class="header-section-number">1.2.1</span> Migration</h3>
<p>Individuals migrate between countries for various reasons, such as the pursuit of work, education and family reunification, or to seek protection. Due to different international rights, a clear legal distinction is made between ‘refugees’ and ‘migrants’. Refugees are defined by the United Nations High Commissioner for Refugees and protected under international law:</p>
<blockquote class="blockquote">
<p>Refugees are persons who are outside their country of origin for reasons of feared persecution, conflict, generalized violence, or other circumstances that have seriously disturbed public order and, as a result, require international protection.<span class="citation" data-cites="unhcrfaq"><sup><a href="references.html#ref-unhcrfaq" role="doc-biblioref">11</a></sup></span></p>
</blockquote>
<p>By contrast, there is no formal legal definition of an international migrant, although anyone changing country of usual residence, irrespective of the reason for migration or legal status, is generally considered a migrant.<span class="citation" data-cites="unhcrfaq"><sup><a href="references.html#ref-unhcrfaq" role="doc-biblioref">11</a></sup></span></p>
<p>In Denmark, applications from migrants seeking protection are processed by authorities to determine if they quality for refugee status, and whether they have previously applied for asylum elsewhere in the European Union under the Dublin Regulation.<span class="citation" data-cites="dublinregulation"><sup><a href="references.html#ref-dublinregulation" role="doc-biblioref">12</a></sup></span> Individuals eligible for refugee status are granted asylum and a residence permit. Conversely, individuals with immediate family members holding Danish citizenship (or a residence permit granted for other reasons than refugee status) can apply for a residence permit on grounds of family reunification before entering the country.<span class="citation" data-cites="familyreunion"><sup><a href="references.html#ref-familyreunion" role="doc-biblioref">13</a></sup></span> Residence permits can also be granted to citizens of the European Union, and to individuals with work or study obligations in Denmark.<span class="citation" data-cites="residencework residencestudy"><sup><a href="references.html#ref-residencework" role="doc-biblioref">14</a>,<a href="references.html#ref-residencestudy" role="doc-biblioref">15</a></sup></span> Citizens of Finland, Iceland, Norway and Sweden are free to enter, reside and work in Denmark.<span class="citation" data-cites="residencenordic"><sup><a href="references.html#ref-residencenordic" role="doc-biblioref">16</a></sup></span></p>
<p>Once residence has been granted, regardless of the reason, an individual has access to the same public healthcare services as a Danish citizen. In addition, any patient in the public healthcare system who is deemed in need of interpreting assistance (by the treating physician) has a right to a professional interpreter. The public healthcare system covers the initial cost of the interpreter services, but since 2018, the regional public healthcare administrations have been obliged by law to charge a fee from patients with more than three years of residence.<span class="citation" data-cites="interpreterlaw"><sup><a href="references.html#ref-interpreterlaw" role="doc-biblioref">17</a></sup></span></p>
</section>
<section id="migrants-in-the-danish-data-infrastructure" class="level3" data-number="1.2.2">
<h3 data-number="1.2.2" class="anchored" data-anchor-id="migrants-in-the-danish-data-infrastructure"><span class="header-section-number">1.2.2</span> Migrants in the Danish data infrastructure</h3>
<p>In this PhD project, refugees and immigrants are referred to collectively as migrants after obtaining residence. The automated, prospective collection of register data in Denmark is challenged by the missing data on migrants and their past.</p>
<p>Basic civil registration data on migrants is collected during processing of residence applications. Generally, registrations pertaining to events that occurred in another country prior to immigration require technical evidence (e.g.&nbsp;clinical imaging to determine age and verify date of birth) or legal proof from the issuing authority of the country where the event occurred. However, in cases where such documentation is unavailable, registrations may be supported by undocumented information provided by the migrant.<span class="citation" data-cites="eventsabroad"><sup><a href="references.html#ref-eventsabroad" role="doc-biblioref">18</a></sup></span> In cases where information was not systematically collected at the time of migration (e.g.&nbsp;an individual’s level of education attained before migration), surveys have been used to collect this data retrospectively, or it may be imputed based on available data.<span class="citation" data-cites="educationmigrants"><sup><a href="references.html#ref-educationmigrants" role="doc-biblioref">19</a></sup></span></p>
</section>
<section id="migrant-groups-in-denmark" class="level3" data-number="1.2.3">
<h3 data-number="1.2.3" class="anchored" data-anchor-id="migrant-groups-in-denmark"><span class="header-section-number">1.2.3</span> Migrant groups in Denmark</h3>
<p>In Danish civil register data, a migrant’s country of origin is defined by Statistics Denmark according to the following rules (paraphrased):</p>
<blockquote class="blockquote">
<p>An immigrant is a person born abroad to non-Danish citizens. If Danish civil records contain data on a migrant’s mother, country of origin is defined by the mother’s country of birth. Otherwise, the father’s country of birth is used, or - if no data is available - country of origin is defined by the country of birth of the immigrant themselves.<span class="citation" data-cites="migrantsdenmark2019"><sup><a href="references.html#ref-migrantsdenmark2019" role="doc-biblioref">20</a></sup></span></p>
</blockquote>
<p>Migrants from more than 200 different countries of origin reside in Denmark, which makes the migrant group very heterogenous with respect to geographic and cultural background.<span class="citation" data-cites="migrantsdenmark2019"><sup><a href="references.html#ref-migrantsdenmark2019" role="doc-biblioref">20</a></sup></span> Furthermore, the context of migration differs greatly between migrants of different origins in terms of when and why a particular minority migrated to Denmark. For example, the vast majority of migrants from Turkey were granted residence due to work and family reunification in the 1960s and 1970s, while almost all migrants from Bosnia-Herzegovina were refugees from the Yugoslav wars of the 1990s. By contrast, migrants from other European countries came to Denmark mainly for work, education or other reasons at various points in time.<span class="citation" data-cites="migrantsdenmark2019"><sup><a href="references.html#ref-migrantsdenmark2019" role="doc-biblioref">20</a></sup></span> <a href="#fig-reason-migration">Figure&nbsp;<span>1.2</span></a> shows the primary reason for migration among the largest migrant groups in Denmark (adapted from Statistics Denmark).<span class="citation" data-cites="dst2022migrants"><sup><a href="references.html#ref-dst2022migrants" role="doc-biblioref">21</a></sup></span></p>
<div id="fig-reason-migration" class="quarto-layout-panel">
<figure class="figure">
<div class="quarto-layout-row quarto-layout-valign-top">
<div class="quarto-layout-cell quarto-layout-cell-subref" style="flex-basis: 100.0%;justify-content: center;">
<div id="fig-reason-western" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<p><img src="figures/reason_migration_origin_west_2022.png" class="img-fluid figure-img" data-ref-parent="fig-reason-migration"></p>
<p></p><figcaption class="figure-caption">(a) Reason for migration: Western countries</figcaption><p></p>
</figure>
</div>
</div>
</div>
<div class="quarto-layout-row quarto-layout-valign-top">
<div class="quarto-layout-cell quarto-layout-cell-subref" style="flex-basis: 100.0%;justify-content: center;">
<div id="fig-reason-nonwestern" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<p><img src="figures/reason_migration_origin_nonwest_2022.png" class="img-fluid figure-img" data-ref-parent="fig-reason-migration"></p>
<p></p><figcaption class="figure-caption">(b) Reason for migration: Non-western countries</figcaption><p></p>
</figure>
</div>
</div>
</div>
<p></p><figcaption class="figure-caption">Figure&nbsp;1.2: <strong>Primary reason for migration among the largest migrant groups in Denmark</strong></figcaption><p></p>
</figure>
</div>
<p>The limited size of each ethnic minority and the strongly contrasting characteristics between them poses a challenge to statistical processing. Minority categories should be clinically meaningful, and researchers must balance the need for aggregation to achieve adequate sample sizes against the risk of introducing biases due to aggregation of dissimilar groups.<span class="citation" data-cites="challengesdatamultiethnic"><sup><a href="references.html#ref-challengesdatamultiethnic" role="doc-biblioref">22</a></sup></span> For statistical purposes, different geoschemes have been used by different institutions depending on the context and purpose. The Statistical Division of the United Nations developed the <em>M49 Standard Country or Area Codes for Statistical Use,<span class="citation" data-cites="m49"><sup><a href="references.html#ref-m49" role="doc-biblioref">23</a></sup></span></em> whereas Statistics Denmark group migrants into Western and Non-western countries, respectively, using a grouping scheme that resembles the more widely-used classification of developed and developing countries.<span class="citation" data-cites="docmigrants"><sup><a href="references.html#ref-docmigrants" role="doc-biblioref">24</a></sup></span> See <a href="3-methods.html">Chapter&nbsp;<span>3</span></a> for a description of grouping of countries of origin in the context of this PhD project.</p>
</section>
<section id="descendants" class="level3" data-number="1.2.4">
<h3 data-number="1.2.4" class="anchored" data-anchor-id="descendants"><span class="header-section-number">1.2.4</span> Descendants</h3>
<p>Descendants of migrants pose an additional challenge to classification for research purposes, as they can be considered part of the migrant group, the native population, or their own distinct category. In the context of T2D today, descendants of migrants in Denmark are a very young group unlikely to constitute a substantial proportion of the patient population (less than 1% of descendants are aged 66 years or older).<span class="citation" data-cites="befpyramide"><sup><a href="references.html#ref-befpyramide" role="doc-biblioref">8</a></sup></span> Some evidence from Sweden suggests that descendants are a distinct group from first-generation immigrants in terms of T2D and mortality.<span class="citation" data-cites="bennetfirstsecondgen"><sup><a href="references.html#ref-bennetfirstsecondgen" role="doc-biblioref">25</a></sup></span> In the context of this PhD project, descendants were not a focus of investigation, and the term migrants specifically refers to first-generation migrants.</p>
</section>
</section>
<section id="type-2-diabetes-care" class="level2" data-number="1.3">
<h2 data-number="1.3" class="anchored" data-anchor-id="type-2-diabetes-care"><span class="header-section-number">1.3</span> Type 2 diabetes care</h2>
<section id="complications-and-risk-factors" class="level3" data-number="1.3.1">
<h3 data-number="1.3.1" class="anchored" data-anchor-id="complications-and-risk-factors"><span class="header-section-number">1.3.1</span> Complications and risk factors</h3>
<section id="overall" class="level4" data-number="1.3.1.1">
<h4 data-number="1.3.1.1" class="anchored" data-anchor-id="overall"><span class="header-section-number">1.3.1.1</span> Overall</h4>
<p>Complications of diabetes are traditionally divided into macrovascular (e.g.&nbsp;<em>cardiovascular disease</em> (CVD)) and microvascular complications (e.g.&nbsp;kidney disease, retinopathy, neuropathy), all of which contribute to morbidity and mortality in T2D. Several lifestyle and physiological factors influence the risk of developing complications, and clinical care revolves around management of these. In addition to being key risk factors of complications, blood pressure and levels of <em>haemoglobin-A1C</em> (HbA1c) and <em>low-density lipoprotein cholesterol</em> (LDL-C) drive indications for treatment and clinical decision-making in T2D.<span class="citation" data-cites="ADA2022"><sup><a href="references.html#ref-ADA2022" role="doc-biblioref">26</a></sup></span></p>
</section>
<section id="in-migrants" class="level4" data-number="1.3.1.2">
<h4 data-number="1.3.1.2" class="anchored" data-anchor-id="in-migrants"><span class="header-section-number">1.3.1.2</span> In migrants</h4>
<p>In Denmark and several other European countries, HbA1c levels are higher in migrants than in native populations,<span class="citation" data-cites="Holm2018 Kristensen2007 Tran2010 Negandhi2013 Rawshani2015 Whyte2019"><sup><a href="references.html#ref-Holm2018" role="doc-biblioref">27</a>–<a href="references.html#ref-Whyte2019" role="doc-biblioref">32</a></sup></span> but LDL-C levels have only been sparsely described.<span class="citation" data-cites="Eastwood2021"><sup><a href="references.html#ref-Eastwood2021" role="doc-biblioref">33</a></sup></span> The evidence on complication risk is inconsistent, but there is some indication that the risk is higher in migrants compared to native populations, although the risks differ between complication types, migrant groups and countries. Similarly, some studies have reported higher mortality among migrants with diabetes,<span class="citation" data-cites="Vandenheede2012 andersen2016"><sup><a href="references.html#ref-andersen2016" role="doc-biblioref">7</a>,<a href="references.html#ref-Vandenheede2012" role="doc-biblioref">34</a></sup></span> whereas other studies have found similar or lower risk.<span class="citation" data-cites="t2d_burden_migrants"><sup><a href="references.html#ref-t2d_burden_migrants" role="doc-biblioref">35</a></sup></span></p>
</section>
</section>
<section id="pharmacological-treatment" class="level3" data-number="1.3.2">
<h3 data-number="1.3.2" class="anchored" data-anchor-id="pharmacological-treatment"><span class="header-section-number">1.3.2</span> Pharmacological treatment</h3>
<section id="overall-1" class="level4" data-number="1.3.2.1">
<h4 data-number="1.3.2.1" class="anchored" data-anchor-id="overall-1"><span class="header-section-number">1.3.2.1</span> Overall</h4>
<p>Due to their effects on HbA1c, LDL-C and blood pressure, <em>glucose-lowering drugs</em> (GLD), <em>lipid-lowering drugs</em> (LLD) and antihypertensive drugs are critical parts of T2D care. In T2D patients with particularly high risk of complications, pharmacological treatment also includes <em>antiplatelet therapy</em> (APT).<span class="citation" data-cites="haller2011arb zoungas2011advance"><sup><a href="references.html#ref-haller2011arb" role="doc-biblioref">36</a>,<a href="references.html#ref-zoungas2011advance" role="doc-biblioref">37</a></sup></span> In addition to their effect on biomarker levels, certain types of the above classes of drugs have other positive effects. In particular, the GLDs <em>sodium glucose co-transporter type 2 inhibitors</em> (SGLT2i) and <em>glucagon-like peptide-1 receptor agonists</em> (GLP1RA) substantially reduce the risk of adverse cardiovascular and renal events beyond their effect on HbA1c. Similarly, the antihypertensive drugs <em>angiotensin-converting enzyme-inhibitors</em> (ACEI) and <em>angiotensin receptor blockers</em> (ARB) reduce the risk and improve the prognosis of <em>diabetic kidney disease</em> (DKD) beyond their effect on blood pressure.<span class="citation" data-cites="chron_kidney_dis"><sup><a href="references.html#ref-chron_kidney_dis" role="doc-biblioref">38</a></sup></span></p>
<p>Combination therapy - the use of multiple drug types with differing mechanisms of action - is a way to increase treatment intensity and achieve treatment goals with fewer side-effects. Combination therapy is particularly important in T2D because GLD monotherapy fails to achieve target levels of HbA1c in many patients, even at maximal dosage.<span class="citation" data-cites="RN237 RN228"><sup><a href="references.html#ref-RN237" role="doc-biblioref">39</a>,<a href="references.html#ref-RN228" role="doc-biblioref">40</a></sup></span></p>
</section>
<section id="in-migrants-1" class="level4" data-number="1.3.2.2">
<h4 data-number="1.3.2.2" class="anchored" data-anchor-id="in-migrants-1"><span class="header-section-number">1.3.2.2</span> In migrants</h4>
<p>Evidence from several European countries shows that GLDs are prescribed earlier and/or to a larger proportion of migrants compared to native populations.<span class="citation" data-cites="Tran2010 Rawshani2015"><sup><a href="references.html#ref-Tran2010" role="doc-biblioref">29</a>,<a href="references.html#ref-Rawshani2015" role="doc-biblioref">31</a></sup></span> However, disparities in the quality of the prescribed GLD treatment, such as the use of combination therapy or the types of GLD prescribed, have not been studied. Indirect evidence suggests that such disparities are likely, as non-white minorities in the UK were found to be slower and less likely to intensify to combination therapy than white groups.<span class="citation" data-cites="RN226"><sup><a href="references.html#ref-RN226" role="doc-biblioref">41</a></sup></span> Likewise, migrants in Italy with T2D have been reported to purchase fewer packages of non-insulin GLDs per person-year than their native counterparts.<span class="citation" data-cites="Marchesini2014"><sup><a href="references.html#ref-Marchesini2014" role="doc-biblioref">42</a></sup></span> Moreover, socioeconomic and racial disparities in prescribing of SGLT2i and GLP1RA have been reported in several countries.<span class="citation" data-cites="RN208 Whyte2019 RN218 RN225 RN211 RN224"><sup><a href="references.html#ref-Whyte2019" role="doc-biblioref">32</a>,<a href="references.html#ref-RN208" role="doc-biblioref">43</a>–<a href="references.html#ref-RN224" role="doc-biblioref">47</a></sup></span></p>
<p>In contrast, studies from European countries have reported lower prescription rates of LLDs in migrants with T2D.<span class="citation" data-cites="Tran2010 RamirezSanchez2013 Eastwood2021"><sup><a href="references.html#ref-Tran2010" role="doc-biblioref">29</a>,<a href="references.html#ref-Eastwood2021" role="doc-biblioref">33</a>,<a href="references.html#ref-RamirezSanchez2013" role="doc-biblioref">48</a></sup></span> However, treatment with LLD is not indicated in all patients with T2D, and only a few of these studies accounted for treatment indication.</p>
<p>Evidence on ACEI/ARB use and APT in migrants with T2D is very limited. A study from Italy found lower odds of treatment in most migrant groups,<span class="citation" data-cites="Marzona2018"><sup><a href="references.html#ref-Marzona2018" role="doc-biblioref">49</a></sup></span> indicating a potential for disparities in these areas of care.</p>
</section>
</section>
<section id="monitoring" class="level3" data-number="1.3.3">
<h3 data-number="1.3.3" class="anchored" data-anchor-id="monitoring"><span class="header-section-number">1.3.3</span> Monitoring</h3>
<section id="overall-2" class="level4" data-number="1.3.3.1">
<h4 data-number="1.3.3.1" class="anchored" data-anchor-id="overall-2"><span class="header-section-number">1.3.3.1</span> Overall</h4>
<p>In T2D, timely monitoring of risk factors and complications allows faster adjustment of treatment, and monitoring has previously been used as a process indicator of care quality, although the direct evidence on its influence on outcomes is sparse.<span class="citation" data-cites="selecting_indicators dvdd"><sup><a href="references.html#ref-selecting_indicators" role="doc-biblioref">50</a>,<a href="references.html#ref-dvdd" role="doc-biblioref">51</a></sup></span></p>
</section>
<section id="in-migrants-2" class="level4" data-number="1.3.3.2">
<h4 data-number="1.3.3.2" class="anchored" data-anchor-id="in-migrants-2"><span class="header-section-number">1.3.3.2</span> In migrants</h4>
<p>The evidence on monitoring of T2D in migrants is inconsistent between countries and different aspects of monitoring. In Norway, migrants with T2D received similar or more monitoring than native Norwegians,<span class="citation" data-cites="Tran2010"><sup><a href="references.html#ref-Tran2010" role="doc-biblioref">29</a></sup></span> while migrants with T2D in Italy received fewer referrals for consultations than native Italians.<span class="citation" data-cites="Marchesini2014"><sup><a href="references.html#ref-Marchesini2014" role="doc-biblioref">42</a></sup></span></p>
</section>
</section>
</section>
<section id="clinical-guidelines-for-type-2-diabetes-care" class="level2" data-number="1.4">
<h2 data-number="1.4" class="anchored" data-anchor-id="clinical-guidelines-for-type-2-diabetes-care"><span class="header-section-number">1.4</span> Clinical guidelines for type 2 diabetes care</h2>
<section id="context" class="level3" data-number="1.4.1">
<h3 data-number="1.4.1" class="anchored" data-anchor-id="context"><span class="header-section-number">1.4.1</span> Context</h3>
<p>In Denmark, T2D care is most often provided by <em>general practitioners</em> (GPs) and other actors in the primary care sector, although some patients are treated in the outpatient hospital setting. The Danish College of General Practitioners publishes national clinical guidelines for T2D in cooperation with the Danish Endocrine Society as well as separate guidelines for pharmacological treatment. Although these guidelines advise that monitoring intervals, biomarker goals and treatment intensity are adapted to fit the individual patient, they do provide specific recommendations that may be used as indicators of care quality.</p>
<section id="migrants-in-guidelines" class="level4" data-number="1.4.1.1">
<h4 data-number="1.4.1.1" class="anchored" data-anchor-id="migrants-in-guidelines"><span class="header-section-number">1.4.1.1</span> Migrants in guidelines</h4>
<p>The Danish guidelines for T2D contain a chapter on vulnerable populations. This chapter includes a section on cultural and language barriers. Here, the special challenges facing migrants in T2D are noted: high prevalence and early onset of disease, poor metabolic control and early onset of complications. The guidelines recommend the use of a professional interpreter when facing language barriers, but specific recommendations on care are not provided. An appendix on ethnic minorities further notes how diabetes-friendly diet and physical exercise can be particularly challenging in these groups, but does not provide recommendations for specific care, except on accomodation of insulin-therapy during religious fasting. In the guidelines on pharmacological treatment of T2D, migrants are not addressed in the main contents, nor in the appendix on treatment of special groups.<span class="citation" data-cites="fbv2022"><sup><a href="references.html#ref-fbv2022" role="doc-biblioref">52</a></sup></span></p>
<p>The sparse recommendations on clinical management of migrants with T2D are not unique to Denmark, however, as guidelines in nearby countries are similarly lacking:</p>
<ul>
<li><p>Sweden: Besides stating the need for providing care regardless of ethnicity or other personal and sociodemographic characteristics, the Swedish guidelines do not mention migrants at all.<span class="citation" data-cites="swedenguidelines"><sup><a href="references.html#ref-swedenguidelines" role="doc-biblioref">53</a></sup></span></p></li>
<li><p>Germany: Ethnicity is noted as one of several contextual factors that may influence morbidity in T2D, but migrants or ethnic minorities are not mentioned otherwise.<span class="citation" data-cites="germanguidelines"><sup><a href="references.html#ref-germanguidelines" role="doc-biblioref">54</a></sup></span></p></li>
<li><p>The Netherlands: The Dutch guidelines recommend increased screening for T2D in individuals of Hindustani, Turkish, Moroccan or Surinamese origin. The guidelines state that provision of diabetes care in these groups should be similar to that in the native Dutch population. No specific recommendations on care in migrants are provided, although it is noted that some treatment options appear to be less effective in these groups (lifestyle interventions, bariatric surgery).<span class="citation" data-cites="dutchguidelines"><sup><a href="references.html#ref-dutchguidelines" role="doc-biblioref">55</a></sup></span></p></li>
<li><p>The United Kingdom: The UK guidelines advise that BMI thresholds for obesity be adjusted in ethnic minorities, and an increased risk of complications in some ethnic groups is noted. No specific recommendations for clinical management of migrants are made. Citing a lack of evidence on ethnicity-specific effects of pharmacological treatment, the guidelines recommend research into the effectiveness of SGLT2i in different ethnic groups.<span class="citation" data-cites="niceguidelines"><sup><a href="references.html#ref-niceguidelines" role="doc-biblioref">56</a></sup></span></p></li>
<li><p>Norway: The special needs of migrants are recognized in the Norwegian guidelines, and a reference group on migrants and diabetes was established among the authors. However, the topic did not receive a separate guideline chapter (the only topic not to do so among all the 13 guideline topics), and the recommendations specific to migrants are limited to more liberal screening for diabetes, use of a professional interpreter, and attention to diet and religious fasting.<span class="citation" data-cites="norwayguidelines"><sup><a href="references.html#ref-norwayguidelines" role="doc-biblioref">57</a></sup></span></p></li>
</ul>
</section>
<section id="historical-revisions" class="level4" data-number="1.4.1.2">
<h4 data-number="1.4.1.2" class="anchored" data-anchor-id="historical-revisions"><span class="header-section-number">1.4.1.2</span> Historical revisions</h4>
<p>The Danish guidelines for type 2 diabetes care have existed for several decades, but a strictly evidence-based format was first introduced in the 2004 revision. This edition included a chapter on T2D in migrants, which recommended the use of a professional interpreter when encountering language barriers and noted a high prevalence and early incidence of T2D in migrants from third-world countries. Notably, this separate chapter on migrants was not included in revisions after 2004.<span class="citation" data-cites="dsam2004"><sup><a href="references.html#ref-dsam2004" role="doc-biblioref">58</a></sup></span></p>
<p>The guidelines are continuously updated as new evidence emerges. In this PhD project, T2D care was studied in the time period covered by the 2012<span class="citation" data-cites="dsam2012"><sup><a href="references.html#ref-dsam2012" role="doc-biblioref">59</a></sup></span> and 2019<span class="citation" data-cites="dsam2019"><sup><a href="references.html#ref-dsam2019" role="doc-biblioref">60</a></sup></span> revisions. These revisions brought minimal changes to the recommendations relevant to this PhD project, as they were largely unchanged from 2004 until the time period of the studies of T2D care in this dissertation. These recommendations are described below as they appeared in the prevailing guidelines at the time, with highlights of any mentioning of migrants.</p>
<p>Some readers will note that parts of the recommendations on pharmacological treatment have been rendered obsolete by newer evidence (e.g.&nbsp;recommendations for SGLT2i and GLP1RA were expanded to include all T2D patients with CVD, multiple risk factors for CVD or chronic kidney disease, irrespective of HbA1c level in the 2022 revision).</p>
</section>
</section>
<section id="diagnosis" class="level3" data-number="1.4.2">
<h3 data-number="1.4.2" class="anchored" data-anchor-id="diagnosis"><span class="header-section-number">1.4.2</span> Diagnosis</h3>
<p>HbA1c is the main diagnostic standard, with values <span class="math inline">\(\ge48 mmol/mol\)</span> being diagnostic of type 2 diabetes, although diagnosis must be confirmed with a repeated sample on a different day, unless symptoms of diabetes are present. HbA1c is not suitable for diagnosis of T2D in certain groups, e.g.&nbsp;pregnant women and individuals with haemoglobinopathy. Once diagnosed, patients with T2D should be considered to be permanently affected by the disease, and the associated risk factors for complications should be treated regardless of subsequent normalisation of HbA1c.</p>
<p>The guidelines mention ethnicity as a risk factor for T2D, and recommend considering HbA1c screening in migrants from Asia, Africa and the Middle East, depending on age and other risk factors.</p>
</section>
<section id="monitoring-1" class="level3" data-number="1.4.3">
<h3 data-number="1.4.3" class="anchored" data-anchor-id="monitoring-1"><span class="header-section-number">1.4.3</span> Monitoring</h3>
<p>The risk biomarkers HbA1c and LDL-C should be measured at least once a year along with urine albumin-to-creatinine ratio (UACR) to screen for DKD (repeated samples of UACR <span class="math inline">\(\ge 300mg/g\)</span> is considering diagnostic of diabetic kidney disease (DKD)). Diabetic retinopathy should be screened by an ophthalmologist every second year, although ophthalmologists can adapt flexible intervals, depending on individual retinopathy status and other risk factors.<span class="citation" data-cites="dos2018"><sup><a href="references.html#ref-dos2018" role="doc-biblioref">61</a></sup></span> Similarly, screening for diabetic foot disease should be performed by a podiatrist every year or, alternatively, by the GP if podiatrist service is not feasible for the patient. At the initial diagnosis of T2D, a baseline-screening of all five types of monitoring is recommended.</p>
<p>The guidelines provide no specific recommendations on monitoring in migrants.</p>
</section>
<section id="biomarker-levels" class="level3" data-number="1.4.4">
<h3 data-number="1.4.4" class="anchored" data-anchor-id="biomarker-levels"><span class="header-section-number">1.4.4</span> Biomarker levels</h3>
<p>For HbA1c, the goal should be the lowest possible level without hypoglycaemia or inappropriate polypharmacy. Specific targets at <span class="math inline">\(48 mmol/mol\)</span>, <span class="math inline">\(53 mmol/mol\)</span>, <span class="math inline">\(58 mmol/mol\)</span>, and <span class="math inline">\(70 mmol/mol\)</span> are provided depending on diabetes duration and severity, complications, age and comorbidities.</p>
<p>For LDL-C, the level should be as low as possible. A general target below <span class="math inline">\(2.6mmol/L\)</span> is provided, while the target in patients with complications should be below <span class="math inline">\(1.8mmol/L\)</span>.</p>
<p>The guidelines provide no specific recommendations on HbA1c or LDL-C targets in migrants.</p>
</section>
<section id="pharmacological-treatment-1" class="level3" data-number="1.4.5">
<h3 data-number="1.4.5" class="anchored" data-anchor-id="pharmacological-treatment-1"><span class="header-section-number">1.4.5</span> Pharmacological treatment</h3>
<section id="glucose-lowering-drugs" class="level4" data-number="1.4.5.1">
<h4 data-number="1.4.5.1" class="anchored" data-anchor-id="glucose-lowering-drugs"><span class="header-section-number">1.4.5.1</span> Glucose-lowering drugs</h4>
<p><strong>Combination therapy:</strong> GLD therapy is recommended in patients with HbA1c ≥ 48 mmol/mol, and metformin is the recommended first-line treatment. There is no overall recommendation of second- or third-line drugs, although SGLT2i or GLP1RA should be considered in patients with CVD when metformin or other treatment is insufficient to reach the patient’s HbA1c target.</p>
<p><strong>Individual drug types:</strong> The guidelines do not present a fixed hierarchy between GLD drug type, but recommend factoring in all effects, positive and negative, as well as cost when choosing between individual drug types.</p>
</section>
<section id="lipid-lowering-drugs" class="level4" data-number="1.4.5.2">
<h4 data-number="1.4.5.2" class="anchored" data-anchor-id="lipid-lowering-drugs"><span class="header-section-number">1.4.5.2</span> Lipid-lowering drugs</h4>
<p>Treatment with LLD is recommended to all individuals with prevalent CVD, diabetic nephropathy or LDL-C above 2.5 mmol/L.</p>
</section>
<section id="antihypertensive-drugs" class="level4" data-number="1.4.5.3">
<h4 data-number="1.4.5.3" class="anchored" data-anchor-id="antihypertensive-drugs"><span class="header-section-number">1.4.5.3</span> Antihypertensive drugs</h4>
<p>In addition to treatment of hypertension, use of either ACEI or ARB is recommended in individuals with prevalent CVD, microalbuminuria, or diabetic kidney disease.</p>
</section>
<section id="antiplatelet-therapy" class="level4" data-number="1.4.5.4">
<h4 data-number="1.4.5.4" class="anchored" data-anchor-id="antiplatelet-therapy"><span class="header-section-number">1.4.5.4</span> Antiplatelet therapy</h4>
<p>APT is recommended in individuals with prevalent CVD, diabetic kidney disease or very high risk of CVD due to other risk factors.</p>
<p>The guidelines provide no specific recommendations on any aspect of pharmacological treatment in migrants.</p>
</section>
</section>
</section>
<section id="sec-id-t2d-registers" class="level2" data-number="1.5">
<h2 data-number="1.5" class="anchored" data-anchor-id="sec-id-t2d-registers"><span class="header-section-number">1.5</span> Identification of type 2 diabetes cases in healthcare registers</h2>
<section id="danish-register-data-infrastructure" class="level3" data-number="1.5.1">
<h3 data-number="1.5.1" class="anchored" data-anchor-id="danish-register-data-infrastructure"><span class="header-section-number">1.5.1</span> Danish register data infrastructure</h3>
<p>Several types of individual-level data (e.g.&nbsp;civil registration, public healthcare contacts, and drug prescriptions) are automatically collected on all residents in Denmark and stored in nationwide Danish registers by Statistics Denmark and the Danish Health Data Authority (see <a href="3-methods.html"><span>Chapter&nbsp;3</span></a> for details on contents of registers). These agencies are legally allowed to share the register data for research purposes, thus creating a set of common data sources shared by researchers with access to the data. Any researcher associated with an approved Danish research institute (mainly Danish universities) can apply for access, but fees and conditions apply.</p>
<p>Register data is generally accessed and processed by approved researchers on remote servers operated by Statistics Denmark and the Danish Health Data Authority, and all researchers can potentially access the same raw data, which are stored in the same structure, unless altered by the researcher (or their data manager). The identical raw data and the common virtual working environment potentially enables reproducible research. This means that any data processing workflow should be transferable between research projects if the underlying code is designed with reproducibility in mind and the code is shared (“open-sourced”).<span class="citation" data-cites="RN184"><sup><a href="references.html#ref-RN184" role="doc-biblioref">62</a></sup></span> While reproducibility in research relates to transparent reporting of methods to enable others to reproduce analyses and experiments, this also applies to a diabetes classification program, which - if reproducible - could be reused by any researcher with access to the necessary register data to dynamically identify a study population of individuals with diabetes for their research needs.<span class="citation" data-cites="RN89"><sup><a href="references.html#ref-RN89" role="doc-biblioref">63</a></sup></span></p>
</section>
<section id="benefits" class="level3" data-number="1.5.2">
<h3 data-number="1.5.2" class="anchored" data-anchor-id="benefits"><span class="header-section-number">1.5.2</span> Benefits</h3>
<p>Healthcare registers provide a powerful data source for population-wide studies without the need to engage the patient for inclusion. The possibility to include all individuals in the population makes them particularly suited for studies of migrants with T2D, where sample size is a limiting factor, and other data sources may be vulnerable to selection bias in these groups.</p>
</section>
<section id="challenges" class="level3" data-number="1.5.3">
<h3 data-number="1.5.3" class="anchored" data-anchor-id="challenges"><span class="header-section-number">1.5.3</span> Challenges</h3>
<p>General-purpose registers and other administrative databases often provide the basis of diabetes epidemiology, but they rarely contain validated diabetes-specific data. If the diabetes-specific data is not accurate, bias may be induced into studies. Thus, it is important to have an accurate tool to identify individuals with diabetes in the registers, as findings may differ with various diabetes definitions.<span class="citation" data-cites="RN165 RN167"><sup><a href="references.html#ref-RN165" role="doc-biblioref">64</a>,<a href="references.html#ref-RN167" role="doc-biblioref">65</a></sup></span> Considerable efforts have been made towards establishing such a tool for diabetes research in several countries, including Denmark.<span class="citation" data-cites="RN166 RN168 RN169"><sup><a href="references.html#ref-RN166" role="doc-biblioref">66</a>–<a href="references.html#ref-RN169" role="doc-biblioref">68</a></sup></span></p>
<p>Internationally, some algorithms classifying T1D and T2D have been validated in cohorts of individuals with diabetes,<span class="citation" data-cites="RN174 RN175 RN176 RN177 RN178"><sup><a href="references.html#ref-RN174" role="doc-biblioref">69</a>–<a href="references.html#ref-RN178" role="doc-biblioref">73</a></sup></span> but none have been validated in a general population. In a general population, classification algorithms (classifiers) must not only discern type 1 diabetes (T1D) from T2D, but it must also identify diabetes while accounting for events that might lead to inclusion of non-cases, such as the use of GLD in the treatment of other conditions. Currently, no type-specific diabetes classifier has been validated in a general population, which leaves register-based studies in this area vulnerable to biases.</p>
</section>
<section id="sec-register-based-diabetes-classifiers" class="level3" data-number="1.5.4">
<h3 data-number="1.5.4" class="anchored" data-anchor-id="sec-register-based-diabetes-classifiers"><span class="header-section-number">1.5.4</span> Register-based diabetes classifiers</h3>
<p>In Denmark, the first resource readily available to researchers to identify diabetes cases through register data was the National Diabetes Register, which was established in 2006.<span class="citation" data-cites="ndr"><sup><a href="references.html#ref-ndr" role="doc-biblioref">74</a></sup></span> The National Diabetes Register was discontinued in 2012, and a later validation study questioned its validity and called for future registers to adopt inclusion based on elevated HbA1c levels.<span class="citation" data-cites="validationndr"><sup><a href="references.html#ref-validationndr" role="doc-biblioref">75</a></sup></span></p>
<p>Launched in 2014, the Register of Selected Chronic Diseases (RSCD) is currently the only publicly available resource to identify diabetes cases through Danish register data (by application to the Danish Health Data Authority), but the RSCD has not been publicly validated, and the source code behind the algorithm has not been made publicly available. Notably, the algorithm lacks inclusion based on elevated HbA1c levels.<span class="citation" data-cites="ruks1doc"><sup><a href="references.html#ref-ruks1doc" role="doc-biblioref">76</a></sup></span></p>
<p>Since the launch of the RSCD, nationwide laboratory data on HbA1c testing has become available in the Danish register ecosystem,<span class="citation" data-cites="rlrr"><sup><a href="references.html#ref-rlrr" role="doc-biblioref">77</a></sup></span> but this data is yet to be incorporated into available diabetes classifiers.</p>
</section>
</section>
<section id="introduction-at-a-glance" class="level2" data-number="1.6">
<h2 data-number="1.6" class="anchored" data-anchor-id="introduction-at-a-glance"><span class="header-section-number">1.6</span> Introduction at a glance</h2>
<p>T2D is a disease that carries serious risks, but several treatment options are available to control the risk factors in T2D and to reduce the risk of complications and death. In an ageing population, the burden of T2D on healthcare services is rising, and resources must be prioritised to those with higher needs to ensure adequate care.</p>
<p>Migrants are particularly vulnerable to T2D, as they have an increased prevalence of the disease compared to native Danes. Despite having higher HbA1c levels than their native counterparts, the evidence on complication risk and mortality in migrants is inconsistent, but some evidence suggests a higher risk. Evidence on care disparities that may contribute to this excess risk in migrants is limited. Additionally, research in this area faces several challenges, such as limited sample sizes and migrants being hard-to-reach for intervention and survey studies. Register-based studies are well-suited to handle these limitations, but no validated method currently exists to identify T2D cases in a general population, which leaves register-based studies in this area vulnerable to biases.</p>
<p>In Denmark, clinical guidelines are available to direct clinicians and patients towards the best possible outcomes. Despite the special challenges faced by migrants, the current guidelines do not contain specific recommendations for T2D care in migrants, and the evidence on care disparities between migrants and native Danes is limited.</p>


<div id="refs" class="references csl-bib-body" role="doc-bibliography" style="display: none">
<div id="ref-socialdiabetes" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">1. </div><div class="csl-right-inline">Agardh E, Allebeck P, Hallqvist J, Moradi T, Sidorchuk A. <span class="nocase">Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysis</span>. International Journal of Epidemiology [Internet] 2011;40(3):804–18. Available from: <a href="https://doi.org/10.1093/ije/dyr029">https://doi.org/10.1093/ije/dyr029</a></div>
</div>
<div id="ref-diabetesatlas" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">2. </div><div class="csl-right-inline">Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice [Internet] 2022;183:109119. Available from: <a href="https://www.sciencedirect.com/science/article/pii/S0168822721004782">https://www.sciencedirect.com/science/article/pii/S0168822721004782</a></div>
</div>
<div id="ref-eurostat_migrants" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">3. </div><div class="csl-right-inline">Eurostat. <span class="nocase">Migrant integration statistics</span> [Internet]. {2022, last accessed 7 Feb 2023};Available from: <a href="https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Migrant_integration_statistics">https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Migrant_integration_statistics</a></div>
</div>
<div id="ref-eurostat_popstruct" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">4. </div><div class="csl-right-inline">Eurostat. <span class="nocase">Population structure and ageing</span> [Internet]. {2022, last accessed 7 Feb 2023};Available from: <a href="https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Population_structure_and_ageing">https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Population_structure_and_ageing</a></div>
</div>
<div id="ref-eurostat_ageing_europe" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">5. </div><div class="csl-right-inline">Eurostat. <span class="nocase">Ageing Europe - statistics on health and disability</span> [Internet]. {2022, last accessed 7 Feb 2023};Available from: <a href="https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Ageing_Europe_-_statistics_on_health_and_disability">https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Ageing_Europe_-_statistics_on_health_and_disability</a></div>
</div>
<div id="ref-meeks2016" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">6. </div><div class="csl-right-inline">Meeks KA, Freitas-Da-Silva D, Adeyemo A, et al. <a href="https://doi.org/10.1007/s11739-015-1302-9"><span class="nocase">Disparities in type 2 diabetes prevalence among ethnic minority groups resident in Europe: a systematic review and meta-analysis</span></a>. Intern Emerg Med 2016;Apr; 11(3):327-40. </div>
</div>
<div id="ref-andersen2016" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">7. </div><div class="csl-right-inline">Andersen GS, Kamper-Jørgensen Z, Carstensen B, Norredam M, Bygbjerg IC, Jørgensen ME. <a href="https://doi.org/10.1016/j.diabres.2016.09.020"><span class="nocase">Diabetes among migrants in Denmark: Incidence, mortality, and prevalence based on a longitudinal register study of the entire Danish population</span></a>. Diabetes Res Clin Pract 2016;Dec:122:9–16. </div>
</div>
<div id="ref-befpyramide" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">8. </div><div class="csl-right-inline">Danmarks Statistik [Statistics Denmark]. <span class="nocase">Befolkningsfremskrivning: Indvandrere og efterkommere [English: Population projection: Immigrants and descendants]</span> [Internet]. {2019-2039; last accessed on 7 Feb 2023};Available from: <a href="https://extranet.dst.dk/pyramide/pyramide.htm#!y=2039&amp;o=2019&amp;c=4">https://extranet.dst.dk/pyramide/pyramide.htm#!y=2039&amp;o=2019&amp;c=4</a></div>
</div>
<div id="ref-nonresponse_migrants" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">9. </div><div class="csl-right-inline">Ahlmark N, Algren MH, Holmberg T, et al. <a href="https://doi.org/10.1080/13557858.2014.979768">Survey nonresponse among ethnic minorities in a national health survey – a mixed-method study of participation, barriers, and potentials</a>. Ethnicity &amp; Health 2015;20(6):611–32. </div>
</div>
<div id="ref-erayil2021raceethnicity" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">10. </div><div class="csl-right-inline">Erayil SE, Smith MK, Gebreslasse T, et al. The value and interpretation of race and ethnicity data in the era of global migration: A change is in order. The American Journal of Tropical Medicine and Hygiene [Internet] 2021;105(6):1453–5. Available from: <a href="https://www.ajtmh.org/view/journals/tpmd/105/6/article-p1453.xml">https://www.ajtmh.org/view/journals/tpmd/105/6/article-p1453.xml</a></div>
</div>
<div id="ref-unhcrfaq" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">11. </div><div class="csl-right-inline">UNHCR. <span class="nocase"><span>“Refugees”</span> and <span>“Migrants”</span> – Frequently Asked Questions (FAQs)</span> [Internet]. {2016; last accessed on 7 Feb 2023};Available from: <a href="https://www.unhcr.org/en-us/news/latest/2016/3/56e95c676/refugees-migrants-frequently-asked-questions-faqs.html">https://www.unhcr.org/en-us/news/latest/2016/3/56e95c676/refugees-migrants-frequently-asked-questions-faqs.html</a></div>
</div>
<div id="ref-dublinregulation" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">12. </div><div class="csl-right-inline">European Commission, Migration and Home Affairs. <span class="nocase">Country responsible for asylum application (Dublin Regulation)</span> [Internet]. {last accessed on 7 Feb 2023};Available from: <a href="https://home-affairs.ec.europa.eu/policies/migration-and-asylum/common-european-asylum-system/country-responsible-asylum-application-dublin-regulation_en">https://home-affairs.ec.europa.eu/policies/migration-and-asylum/common-european-asylum-system/country-responsible-asylum-application-dublin-regulation_en</a></div>
</div>
<div id="ref-familyreunion" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">13. </div><div class="csl-right-inline">The Danish Immigration Service. <span class="nocase">New to Denmark: You want to apply as a family member</span> [Internet]. {last accessed on 7 Feb 2023};Available from: <a href="https://nyidanmark.dk/uk-UA/You-want-to-apply/Family">https://nyidanmark.dk/uk-UA/You-want-to-apply/Family</a></div>
</div>
<div id="ref-residencework" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">14. </div><div class="csl-right-inline">The Danish Immigration Service. <span class="nocase">New to Denmark: You want to apply for a work permit</span> [Internet]. {last accessed on 7 Feb 2023};Available from: <a href="https://nyidanmark.dk/uk-UA/You-want-to-apply/Work">https://nyidanmark.dk/uk-UA/You-want-to-apply/Work</a></div>
</div>
<div id="ref-residencestudy" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">15. </div><div class="csl-right-inline">The Danish Immigration Service. <span class="nocase">New to Denmark: You want to apply for a residence and work permit as a student</span> [Internet]. {last accessed on 7 Feb 2023};Available from: <a href="https://nyidanmark.dk/uk-UA/You-want-to-apply/Study">https://nyidanmark.dk/uk-UA/You-want-to-apply/Study</a></div>
</div>
<div id="ref-residencenordic" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">16. </div><div class="csl-right-inline">The Danish Immigration Service. <span class="nocase">New to Denmark: Nordic citizens</span> [Internet]. {last accessed on 7 Feb 2023};Available from: <a href="https://nyidanmark.dk/uk-UA/You-want-to-apply/Residence-as-a-Nordic-citizen-or-EU-or-EEA-citizen/Nordic-citizens">https://nyidanmark.dk/uk-UA/You-want-to-apply/Residence-as-a-Nordic-citizen-or-EU-or-EEA-citizen/Nordic-citizens</a></div>
</div>
<div id="ref-interpreterlaw" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">17. </div><div class="csl-right-inline">Indenrigs- og Boligministeriet [English: Ministry of the Interior and Health]. <span class="nocase">Bekendtgørelse om tolkebistand efter sundhedsloven [English: Executive Order on Interpretation Services under the Health Care Act]</span> [Internet]. {2018; last accessed on 7 Feb 2023};Available from: <a href="https://www.retsinformation.dk/eli/lta/2018/855">https://www.retsinformation.dk/eli/lta/2018/855</a></div>
</div>
<div id="ref-eventsabroad" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">18. </div><div class="csl-right-inline">Indenrigs- og Boligministeriet [English: Ministry of the Interior and Housing]. <span class="nocase">Vejledning om folkeregistrering, bilag 1: Registrering af hændelser i udlandet [English: Civil registration guidelines, appendix 1: Registration of events abroad]</span> [Internet]. {2013; last accessed on 7 Feb 2023};Available from: <a href="https://www.retsinformation.dk/eli/retsinfo/2013/9273#Bil1">https://www.retsinformation.dk/eli/retsinfo/2013/9273#Bil1</a></div>
</div>
<div id="ref-educationmigrants" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">19. </div><div class="csl-right-inline">Danmarks Statistik [English: Statistics Denmark]. <span class="nocase">Indvandrernes medbragte uddannelse [English: Education carried by immigrants]</span> [Internet]. {2020; last accessed on 7 Feb 2023};Available from: <a href="https://www.dst.dk/Site/Dst/SingleFiles/GetArchiveFile.aspx?fi=formid&amp;fo=medbragt-udd--pdf">https://www.dst.dk/Site/Dst/SingleFiles/GetArchiveFile.aspx?fi=formid&amp;fo=medbragt-udd--pdf</a></div>
</div>
<div id="ref-migrantsdenmark2019" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">20. </div><div class="csl-right-inline">Danmarks Statistik [English: Statistics Denmark]. <span class="nocase">Indvandrere i Danmark 2019 [English: Immigrants in Denmark 2019]</span> [Internet]. {2019; last accessed on 7 Feb 2023};Available from: <a href="https://www.dst.dk/Site/Dst/Udgivelser/GetPubFile.aspx?id=29446&amp;sid=indv2019">https://www.dst.dk/Site/Dst/Udgivelser/GetPubFile.aspx?id=29446&amp;sid=indv2019</a></div>
</div>
<div id="ref-dst2022migrants" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">21. </div><div class="csl-right-inline">Danmarks Statistik [English: Statistics Denmark]. <span class="nocase">Fakta om indvandrere og efterkommere i Danmark [English: Facts on immigrants and descendants in Denmark]</span> [Internet]. {2022; last accessed on 7 Feb 2023};Available from: <a href="https://www.dst.dk/da/Statistik/nyheder-analyser-publ/bagtal/2022/2022-08-18-fakta-om-indvandrere">https://www.dst.dk/da/Statistik/nyheder-analyser-publ/bagtal/2022/2022-08-18-fakta-om-indvandrere</a></div>
</div>
<div id="ref-challengesdatamultiethnic" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">22. </div><div class="csl-right-inline">Kaneshiro B, Geling O, Gellert K, Millar L. The challenges of collecting data on race and ethnicity in a diverse, multiethnic state. Hawaii Med J 2011;70(8):168–71. </div>
</div>
<div id="ref-m49" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">23. </div><div class="csl-right-inline">United Nations Statistics Division. <span class="nocase">Standard country or area codes for statistical use (M49)</span> [Internet]. {2022; last accessed on 7 Feb 2023};Available from: <a href="https://unstats.un.org/unsd/methodology/m49/">https://unstats.un.org/unsd/methodology/m49/</a></div>
</div>
<div id="ref-docmigrants" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">24. </div><div class="csl-right-inline">Statistics Denmark. <span class="nocase">Documentation of statistics for Population Projections 2019</span> [Internet]. {2019; last accessed on 7 Feb 2023};Available from: <a href="https://www.dst.dk/Site/Dst/SingleFiles/GetArchiveFile.aspx?fi=49459100303&amp;fo=0&amp;ext=kvaldel">https://www.dst.dk/Site/Dst/SingleFiles/GetArchiveFile.aspx?fi=49459100303&amp;fo=0&amp;ext=kvaldel</a></div>
</div>
<div id="ref-bennetfirstsecondgen" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">25. </div><div class="csl-right-inline">Bennet L, Udumyan R, Östgren CJ, Rolandsson O, Jansson SPO, Wändell P. <a href="https://doi.org/10.1007/s00125-020-05279-1">Mortality in first- and second-generation immigrants to sweden diagnosed with type 2 diabetes: A 10&nbsp;year nationwide cohort study</a>. Diabetologia 2021;64(1):95–108. </div>
</div>
<div id="ref-ADA2022" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">26. </div><div class="csl-right-inline">American Diabetes Association Professional Practice Committee. <span class="nocase">2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022</span>. Diabetes Care [Internet] 2021;45(Supplement_1):S17–38. Available from: <a href="https://doi.org/10.2337/dc22-S002">https://doi.org/10.2337/dc22-S002</a></div>
</div>
<div id="ref-Holm2018" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">27. </div><div class="csl-right-inline">Holm AL, Andersen GS, Diderichsen F, Jørgensen ME. <a href="https://doi.org/10.1136/bmjopen-2018-023211"><span class="nocase">Is the Rule of Halves framework relevant for diabetes care in <span>Copenhagen</span> today? A register-based cross-sectional study</span></a>. BMJ Open 2018;8:e023211. </div>
</div>
<div id="ref-Kristensen2007" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">28. </div><div class="csl-right-inline">Kristensen J, Bak J, Wittrup I, Lauritzen T. <a href="https://doi.org/10.1016/j.pcd.2007.07.007"><span class="nocase">Diabetes prevalence and quality of diabetes care among Lebanese or Turkish immigrants compared to a native Danish population</span></a>. Prim Care Diabetes 2007;Sep:1(3):159–65. </div>
</div>
<div id="ref-Tran2010" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">29. </div><div class="csl-right-inline">Tran AT, Diep LM, Cooper JG, et al. <a href="https://doi.org/10.1186/1472-6963-10-145"><span class="nocase">Quality of care for patients with type 2 diabetes in general practice according to patients’ ethnic background: a cross-sectional study from Oslo, Norway</span></a>. BMC Health Serv Res 2010;10, 145. </div>
</div>
<div id="ref-Negandhi2013" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">30. </div><div class="csl-right-inline">Negandhi PH, Ghouri N, Colhoun HM, et al. <a href="https://doi.org/10.1371/journal.pone.0083292"><span class="nocase">Ethnic Differences in Glycaemic Control in People with Type 2 Diabetes Mellitus Living in Scotland</span></a>. PLoS ONE 2013;8. </div>
</div>
<div id="ref-Rawshani2015" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">31. </div><div class="csl-right-inline">Rawshani A, Svensson A, Rosengren A, Zethelius B, Eliasson B, Gudbjörnsdottir S. <a href="https://doi.org/10.1136/bmjopen-2015-007599"><span class="nocase">Impact of ethnicity on progress of glycaemic control in 131935 newly diagnosed patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register</span></a>. BMJ Open 2015;5;e007599. </div>
</div>
<div id="ref-Whyte2019" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">32. </div><div class="csl-right-inline">Whyte MB, Hinton W, McGovern A, et al. <a href="https://doi.org/10.1371/journal.pmed.1002942"><span class="nocase">Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis</span></a>. PLoS Med 2019;Oct 7; 16(10):e1002942. </div>
</div>
<div id="ref-Eastwood2021" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">33. </div><div class="csl-right-inline">Eastwood SV, Mathur R, Sattar N, Smeeth L, Bhaskaran K, Chaturvedi N. <a href="https://doi.org/10.1371/journal.pmed.1003672"><span class="nocase">Ethnic differences in guideline-indicated statin initiation for people with type 2 diabetes in UK primary care, 2006-2019: A cohort study</span></a>. PLoS Med 2021;18. </div>
</div>
<div id="ref-Vandenheede2012" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">34. </div><div class="csl-right-inline">Vandenheede H, Deboosere P, Stirbu I, et al. <a href="https://doi.org/10.1007/s10654-011-9638-6"><span class="nocase">Migrant mortality from diabetes mellitus across Europe: the importance of socio-economic change</span></a>. Eur J Epidemiol 2012;Feb; 27(2):109-17. </div>
</div>
<div id="ref-t2d_burden_migrants" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">35. </div><div class="csl-right-inline">Agyemang C, Linden EL van der, Bennet L. Type 2 diabetes burden among migrants in europe: Unravelling the causal pathways. Diabetologia [Internet] 2021;64(12):2665–75. Available from: <a href="https://doi.org/10.1007/s00125-021-05586-1">https://doi.org/10.1007/s00125-021-05586-1</a></div>
</div>
<div id="ref-haller2011arb" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">36. </div><div class="csl-right-inline">Haller H, Ito S, Izzo JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. New England Journal of Medicine [Internet] 2011;364(10):907–17. Available from: <a href="https://doi.org/10.1056/NEJMoa1007994">https://doi.org/10.1056/NEJMoa1007994</a></div>
</div>
<div id="ref-zoungas2011advance" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">37. </div><div class="csl-right-inline">Zoungas S, Galan BE de, Ninomiya T, et al. <span class="nocase">Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes: New results from the ADVANCE trial</span>. Diabetes Care [Internet] 2009;32(11):2068–74. Available from: <a href="https://doi.org/10.2337/dc09-0959">https://doi.org/10.2337/dc09-0959</a></div>
</div>
<div id="ref-chron_kidney_dis" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">38. </div><div class="csl-right-inline">Stephens JW, Brown KE, Min T. Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk. Diabetes, Obesity and Metabolism [Internet] 2020;22(S1):32–45. Available from: <a href="https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.13942">https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.13942</a></div>
</div>
<div id="ref-RN237" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">39. </div><div class="csl-right-inline">Kim K, Unni S, Brixner DI, et al. Longitudinal changes in glycated haemoglobin following treatment intensification after inadequate response to two oral antidiabetic agents in patients with type 2 diabetes. Diabetes, Obesity and Metabolism [Internet] 2019;21(7):1725–33. Available from: <a href="https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.13694">https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.13694</a></div>
</div>
<div id="ref-RN228" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">40. </div><div class="csl-right-inline">Bonnet F, Chen H, Cooper A, et al. What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (≥7.0. Diabetes, Obesity and Metabolism [Internet] 2021;23(10):2336–43. Available from: <a href="https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.14476">https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.14476</a></div>
</div>
<div id="ref-RN226" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">41. </div><div class="csl-right-inline">Mathur R, Farmer RE, Eastwood SV, Chaturvedi N, Douglas I, Smeeth L. <a href="https://doi.org/10.1371/journal.pmed.1003106">Ethnic disparities in initiation and intensification of diabetes treatment in adults with type 2 diabetes in the UK, 1990-2017: A cohort study</a>. PLoS Med 2020;17(5):e1003106. </div>
</div>
<div id="ref-Marchesini2014" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">42. </div><div class="csl-right-inline">Marchesini G, Bernardi D, Miccoli R, et al. <a href="https://doi.org/10.1016/j.numecd.2013.09.012"><span class="nocase">Under-treatment of migrants with diabetes in a universalistic health care system: The ARNO Observatory</span></a>. Nutr Metab Cardiovasc Dis 2014;24. </div>
</div>
<div id="ref-RN208" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">43. </div><div class="csl-right-inline">Vasti EC, Basina M, Calma J, Maron DJ, Rodriguez F, Sandhu AT. Disparities in adoption of new diabetic therapies with cardiovascular benefits. Diabetes Research and Clinical Practice [Internet] 2022;110233. Available from: <a href="https://www.sciencedirect.com/science/article/pii/S0168822722010476">https://www.sciencedirect.com/science/article/pii/S0168822722010476</a></div>
</div>
<div id="ref-RN218" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">44. </div><div class="csl-right-inline">Morton JI, Ilomӓki J, Magliano DJ, Shaw JE. The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in australia: A nationwide registry study. Diabetologia [Internet] 2021;64(2):349–60. Available from: <a href="https://doi.org/10.1007/s00125-020-05304-3">https://doi.org/10.1007/s00125-020-05304-3</a></div>
</div>
<div id="ref-RN225" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">45. </div><div class="csl-right-inline">Elhussein A, Anderson A, Bancks MP, et al. <a href="https://doi.org/10.1016/j.lana.2021.100111">Racial/ethnic and socioeconomic disparities in the use of newer diabetes medications in the look AHEAD study</a>. Lancet Reg Health Am 2022;6. </div>
</div>
<div id="ref-RN211" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">46. </div><div class="csl-right-inline">Falkentoft AC, Andersen J, Malik ME, et al. Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes – a danish nationwide observational study. The Lancet Regional Health - Europe [Internet] 2022;14:100308. Available from: <a href="https://www.sciencedirect.com/science/article/pii/S2666776222000011">https://www.sciencedirect.com/science/article/pii/S2666776222000011</a></div>
</div>
<div id="ref-RN224" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">47. </div><div class="csl-right-inline">Nicolucci A, Charbonnel B, Gomes MB, et al. Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme. Diabetes, Obesity and Metabolism [Internet] 2019;21(11):2474–85. Available from: <a href="https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.13830">https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.13830</a></div>
</div>
<div id="ref-RamirezSanchez2013" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">48. </div><div class="csl-right-inline">Ramirez-Sanchez DC, Krasnik A, Kildemoes HW. <a href="https://doi.org/10.1007/s00228-012-1306-6"><span class="nocase">Do immigrants from Turkey, Pakistan and Ex-Yugoslavia with newly diagnosed type 2 diabetes initiate recommended statin therapy to the same extent as Danish-born residents? A nationwide register study</span></a>. Eur J Clin Pharmacol 2013;69:87–95. </div>
</div>
<div id="ref-Marzona2018" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">49. </div><div class="csl-right-inline">Marzona I, Avanzini F, Tettamanti M, et al. <a href="https://doi.org/10.1007/s00592-018-1102-6"><span class="nocase">Prevalence and management of diabetes in immigrants resident in the Lombardy Region: the importance of ethnicity and duration of stay</span></a>. Acta Diabetol 2018;55:355–62. </div>
</div>
<div id="ref-selecting_indicators" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">50. </div><div class="csl-right-inline">Nicolucci A, Greenfield S, Mattke S. <span class="nocase">Selecting indicators for the quality of diabetes care at the health systems level in OECD countries</span>. International Journal for Quality in Health Care [Internet] 2006;18(suppl_1):26–30. Available from: <a href="https://doi.org/10.1093/intqhc/mzl023">https://doi.org/10.1093/intqhc/mzl023</a></div>
</div>
<div id="ref-dvdd" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">51. </div><div class="csl-right-inline">Jørgensen ME, Kristensen JK, Reventlov Husted G, Cerqueira C, Rossing P. The danish adult diabetes registry. Clinical epidemiology [Internet] 2016;8:429–34. Available from: <a href="https://www.ncbi.nlm.nih.gov/pubmed/27843339
https://www.ncbi.nlm.nih.gov/pmc/PMC5098513/">https://www.ncbi.nlm.nih.gov/pubmed/27843339 https://www.ncbi.nlm.nih.gov/pmc/PMC5098513/</a></div>
</div>
<div id="ref-fbv2022" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">52. </div><div class="csl-right-inline">Dansk Selskab for Almen Medicin &amp; Dansk Endokrinologisk Selskab [English: The Danish College of General Practitioners &amp; The Danish Endocrine Society. <span class="nocase">Farmakologisk behandling af type 2-diabetes [English: Pharmacological treatment of type 2 diabetes]</span> [Internet]. {2022; 2023 revision};Available from: <a href="https://vejledninger.dsam.dk/fbv-t2dm/">https://vejledninger.dsam.dk/fbv-t2dm/</a></div>
</div>
<div id="ref-swedenguidelines" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">53. </div><div class="csl-right-inline">Socialstyrelsen [English: The National Board of Health and Welfare]. <span class="nocase">Nationella riktlinjer för diabetesvård [English: National guidelines for diabetes care]</span> [Internet]. 2018;Available from: <a href="https://www.socialstyrelsen.se/kunskapsstod-och-regler/regler-och-riktlinjer/nationella-riktlinjer/riktlinjer-och-utvarderingar/diabetes/">https://www.socialstyrelsen.se/kunskapsstod-och-regler/regler-och-riktlinjer/nationella-riktlinjer/riktlinjer-och-utvarderingar/diabetes/</a></div>
</div>
<div id="ref-germanguidelines" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">54. </div><div class="csl-right-inline">Nationale VersorgungsLeitlinie [English: National Care Guidelines]. <span>NVL Typ-2-Diabetes</span> [Internet]. 2021;Available from: <a href="https://www.leitlinien.de/themen/diabetes/2-auflage/">https://www.leitlinien.de/themen/diabetes/2-auflage/</a></div>
</div>
<div id="ref-dutchguidelines" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">55. </div><div class="csl-right-inline">Nederlands Huisarten Genootschap [English: Dutch College of General Practitioners]. <span class="nocase">NHG STANDARD: Diabetes mellitus type 2</span> [Internet]. {2018, latest revision January 2023};Available from: <a href="https://richtlijnen.nhg.org/standaarden/diabetes-mellitus-type-2">https://richtlijnen.nhg.org/standaarden/diabetes-mellitus-type-2</a></div>
</div>
<div id="ref-niceguidelines" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">56. </div><div class="csl-right-inline">National Institute for Health and Care Excellence. <span class="nocase">NICE guideline [NG28]: Type 2 diabetes in adults: management</span> [Internet]. {2015, latest revision June 2022};Available from: <a href="https://www.nice.org.uk/guidance/ng28">https://www.nice.org.uk/guidance/ng28</a></div>
</div>
<div id="ref-norwayguidelines" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">57. </div><div class="csl-right-inline">Helsedirektoratet [English: Norwegian Directorate of Health]. <span class="nocase">Nasjonal faglig retningslinje for diabetes [English: National professional guideline for diabetes]</span> [Internet]. {2016, latest revision March 2021};Available from: <a href="https://www.helsedirektoratet.no/retningslinjer/diabetes">https://www.helsedirektoratet.no/retningslinjer/diabetes</a></div>
</div>
<div id="ref-dsam2004" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">58. </div><div class="csl-right-inline">Dansk Selskab for Almen Medicin [English: The Danish College of General Practitioners]. <span class="nocase">Type 2-diabetes i almen praksis - en evidensbaseret vejledning [English: Type 2 diabetes in general practice - an evidence-based guideline]</span> [Internet]. {2004; last accessed on 7 Feb 2023};Available from: <a href="https://vejledninger.dsam.dk/media/files/20/type_2_diabetes_2004_rettet.pdf">https://vejledninger.dsam.dk/media/files/20/type_2_diabetes_2004_rettet.pdf</a></div>
</div>
<div id="ref-dsam2012" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">59. </div><div class="csl-right-inline">Dansk Selskab for Almen Medicin [English: The Danish College of General Practitioners]. <span class="nocase">Type 2-diabetes - et metabolisk syndrom [English: Type 2 diabetes - a metabolic syndrome]</span> [Internet]. {2012; last accessed on 7 Feb 2023};Available from: <a href="https://vejledninger.dsam.dk/media/files/20/type-2-diabetes-2012-med-links.pdf">https://vejledninger.dsam.dk/media/files/20/type-2-diabetes-2012-med-links.pdf</a></div>
</div>
<div id="ref-dsam2019" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">60. </div><div class="csl-right-inline">Dansk Selskab for Almen Medicin [English: The Danish College of General Practitioners]. <span class="nocase">Type 2-diabetes - opfølgning og behandling [English: Type 2 diabetes - follow-up and treatment]</span> [Internet]. {2019; last accessed on 7 Feb 2023};Available from: <a href="https://vejledninger.dsam.dk/type2/">https://vejledninger.dsam.dk/type2/</a></div>
</div>
<div id="ref-dos2018" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">61. </div><div class="csl-right-inline">Danish Ophthalmological Society. <span class="nocase">National retningslinje for screening for diabetisk retinopati [English: National guideline on screening for diabetic retinopathy]</span> [Internet]. {2018; last accessed on 7 Feb 2023};Available from: <a href="https://dansk-oftalmologisk-selskab.dk/wp-content/uploads/2021/05/National-retningslinje-for-screening-af-diabetisk-retinopati.pdf">https://dansk-oftalmologisk-selskab.dk/wp-content/uploads/2021/05/National-retningslinje-for-screening-af-diabetisk-retinopati.pdf</a></div>
</div>
<div id="ref-RN184" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">62. </div><div class="csl-right-inline">Marszalek RT, Flintoft L. Being open: Our policy on source code. Genome Biology [Internet] 2016;17(1):172. Available from: <a href="https://doi.org/10.1186/s13059-016-1040-y">https://doi.org/10.1186/s13059-016-1040-y</a></div>
</div>
<div id="ref-RN89" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">63. </div><div class="csl-right-inline">Dima AL, Dediu D. <a href="https://doi.org/10.1371/journal.pone.0174426">Computation of adherence to medication and visualization of medication histories in r with AdhereR: Towards transparent and reproducible use of electronic healthcare data</a>. PLoS One 2017;12(4):e0174426. </div>
</div>
<div id="ref-RN165" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">64. </div><div class="csl-right-inline">Nielsen AA, Christensen H, Lund ED, Christensen C, Brandslund I, Green A. Diabetes mortality differs between registers due to various disease definitions. Dan Med J 2014;61(5):A4840. </div>
</div>
<div id="ref-RN167" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">65. </div><div class="csl-right-inline">Rawshani A, Landin-Olsson M, Svensson AM, et al. <a href="https://doi.org/10.1007/s00125-014-3225-9">The incidence of diabetes among 0-34 year olds in sweden: New data and better methods</a>. Diabetologia 2014;57(7):1375–81. </div>
</div>
<div id="ref-RN166" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">66. </div><div class="csl-right-inline">Bak JCG, Serné EH, Kramer MHH, Nieuwdorp M, Verheugt CL. National diabetes registries: Do they make a difference? Acta Diabetologica [Internet] 2021;58(3):267–78. Available from: <a href="https://doi.org/10.1007/s00592-020-01576-8">https://doi.org/10.1007/s00592-020-01576-8</a></div>
</div>
<div id="ref-RN168" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">67. </div><div class="csl-right-inline">Hallgren Elfgren I-M, Grodzinsky E, Törnvall E. The swedish national diabetes register in clinical practice and evaluation in primary health care. Primary Health Care Research &amp;amp; Development [Internet] 2016;17(6):549–58. Available from: <a href="https://www.cambridge.org/core/article/swedish-national-diabetes-register-in-clinical-practice-and-evaluation-in-primary-health-care/F3A9B74FED1E7B36147FF63382939B9A">https://www.cambridge.org/core/article/swedish-national-diabetes-register-in-clinical-practice-and-evaluation-in-primary-health-care/F3A9B74FED1E7B36147FF63382939B9A</a></div>
</div>
<div id="ref-RN169" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">68. </div><div class="csl-right-inline">Cooper JG, Thue G, Claudi T, Løvaas K, Carlsen S, Sandberg S. The norwegian diabetes register for adults – an overview of the first years. Norsk Epidemiologi [Internet] 2013;23(1). Available from: <a href="https://www.ntnu.no/ojs/index.php/norepid/article/view/1599">https://www.ntnu.no/ojs/index.php/norepid/article/view/1599</a></div>
</div>
<div id="ref-RN174" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">69. </div><div class="csl-right-inline">Klompas M, Eggleston E, McVetta J, Lazarus R, Li L, Platt R. <a href="https://doi.org/10.2337/dc12-0964">Automated detection and classification of type 1 versus type 2 diabetes using electronic health record data</a>. Diabetes Care 2013;36(4):914–21. </div>
</div>
<div id="ref-RN175" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">70. </div><div class="csl-right-inline">Schroeder EB, Donahoo WT, Goodrich GK, Raebel MA. <a href="https://doi.org/10.1002/pds.4377">Validation of an algorithm for identifying type 1 diabetes in adults based on electronic health record data</a>. Pharmacoepidemiol Drug Saf 2018;27(10):1053–9. </div>
</div>
<div id="ref-RN176" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">71. </div><div class="csl-right-inline">Lo-Ciganic W, Zgibor JC, Ruppert K, Arena VC, Stone RA. <a href="https://doi.org/10.1177/193229681100500303">Identifying type 1 and type 2 diabetic cases using administrative data: A tree-structured model</a>. J Diabetes Sci Technol 2011;5(3):486–93. </div>
</div>
<div id="ref-RN177" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">72. </div><div class="csl-right-inline">Weisman A, Tu K, Young J, et al. <a href="https://doi.org/10.1136/bmjdrc-2020-001224">Validation of a type 1 diabetes algorithm using electronic medical records and administrative healthcare data to study the population incidence and prevalence of type 1 diabetes in ontario, canada</a>. BMJ Open Diabetes Res Care 2020;8(1). </div>
</div>
<div id="ref-RN178" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">73. </div><div class="csl-right-inline">Lynam A, McDonald T, Hill A, et al. <a href="https://doi.org/10.1136/bmjopen-2019-031586">Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18-50 years</a>. BMJ Open 2019;9(9):e031586. </div>
</div>
<div id="ref-ndr" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">74. </div><div class="csl-right-inline">Carstensen B, Kristensen JK, Marcussen MM, Borch-Johnsen K. <a href="https://doi.org/10.1177/1403494811404278">The national diabetes register</a>. Scand J Public Health 2011;39(7 Suppl):58–61. </div>
</div>
<div id="ref-validationndr" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">75. </div><div class="csl-right-inline">Green A, Sortsø C, Jensen PB, Emneus M. Validation of the danish national diabetes register. Clinical epidemiology [Internet] 2014;7:5–15. Available from: <a href="https://www.ncbi.nlm.nih.gov/pubmed/25565889
https://www.ncbi.nlm.nih.gov/pmc/PMC4274151/">https://www.ncbi.nlm.nih.gov/pubmed/25565889 https://www.ncbi.nlm.nih.gov/pmc/PMC4274151/</a></div>
</div>
<div id="ref-ruks1doc" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">76. </div><div class="csl-right-inline">Sundhedsdatastyrelsen [English: Danish Health Data Authority]. <span class="nocase">Algoritmer for udvalgte kroniske sygdomme og svære psykiske lidelser [English: Algorithms for selected chronic diseases and serious mental illnesses]</span> [Internet]. {2016, last accessed 7 Feb 2023};Available from: <a href="https://www.esundhed.dk/-/media/Files/Dokumentation/Register-for-Udvalgte-Kroniske-Sygdomme-og-Svaere-Psykiske-Lidelser/29_Algoritmer_for_RUKS.ashx">https://www.esundhed.dk/-/media/Files/Dokumentation/Register-for-Udvalgte-Kroniske-Sygdomme-og-Svaere-Psykiske-Lidelser/29_Algoritmer_for_RUKS.ashx</a></div>
</div>
<div id="ref-rlrr" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">77. </div><div class="csl-right-inline">Sundhedsdatastyrelsen [English: Danish Health Data Authority]. <span class="nocase">Dokumentation af Laboratoriedatabasens Forskertabel – Version 1.3 [English: Documentation on Register of Laboratory Results for Research - version 1.3]</span> [Internet]. {2018, last accessed 7 Feb 2023};Available from: <a href="https://sundhedsdatastyrelsen.dk/-/media/sds/filer/registre-og-services/nationale-sundhedsregistre/doedsaarsager-og-biologisk-materiale/laboratoriedatabasen/dokumentation-af-labdatabasens-forskertabel.pdf">https://sundhedsdatastyrelsen.dk/-/media/sds/filer/registre-og-services/nationale-sundhedsregistre/doedsaarsager-og-biologisk-materiale/laboratoriedatabasen/dokumentation-af-labdatabasens-forskertabel.pdf</a></div>
</div>
</div>
</section>

</main> <!-- /main -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    target: function(trigger) {
      return trigger.previousElementSibling;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
<nav class="page-navigation">
  <div class="nav-page nav-page-previous">
      <a href="./0-abbreviations.html" class="pagination-link">
        <i class="bi bi-arrow-left-short"></i> <span class="nav-page-text">Abbreviations</span>
      </a>          
  </div>
  <div class="nav-page nav-page-next">
      <a href="./2-aims.html" class="pagination-link">
        <span class="nav-page-text"><span class="chapter-number">2</span>&nbsp; <span class="chapter-title">Aims</span></span> <i class="bi bi-arrow-right-short"></i>
      </a>
  </div>
</nav>
</div> <!-- /content -->



</body></html>